Use of esculentin and its derivatives for use in the treatment of cystic fibrosis
AssigneesUniversita' Degli Studi Di Roma “La Sapienza”, Fondazione Per La Ricerca Sulla Fibrosi Cistica, Istituto Giannina Gaslini
InventorsMaria Luisa Mangoni, Loretta Ferrera
Life of this patent
Estimating the term…
Abstract
Are disclosed pharmaceutical compositions comprising as active ingredients Esculentin-1a(1-21)NH2 and/or Esculentin diastereomer Esc(1-21)-1c for use for restoring dysregulation of water and/or ions content and/or composition of the periciliary liquid due to mutations of the CFTR gene encoding for Cystic fibrosis transmembrane conductance regulator (CFTR) and for use for the treatment of cystic fibrosis.
Claims6
A method for treating cystic fibrosis in an individual in need thereof who does not have a P. aeruginosa infection, the method comprising:
- (a) selecting an individual diagnosed with cystic fibrosis who does not have a P. aeruginosa infection;
- (b) providing a pharmaceutical formulation comprising:
- (1) a pharmaceutically active ingredient comprising:
- (i) an esculentin-1a(1-21)NH2 peptide having an amino acid sequence as set forth in SEQ ID NO:2;
- or
- (ii) an esculentin diastereomer Esc(1-21)-1c having an amino acid sequence as set forth in SEQ ID NO:3;
- and
- (2) a pharmaceutically acceptable adjuvant, vehicle or excipient, and
- (c) administering the pharmaceutical formulation to the individual who does not have a P. aeruginosa infection.
Dependencies are inferred from the claim text.